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Summary To investigate the role of tumour-suppressor genes on the short arm of chromosome 3 in the
mechanism of tumorigenesis in non-familial renal cell carcinoma, we analysed 55 paired blood-tumour DNA
samples for allele loss on chromosome 3p and in the region of known or putative tumour-suppressor genes on
chromosomes 5, 11, 17 and 22. Sixty-four per cent (35/55) of informative tumours showed loss of
heterozygosity (LOH) of at least one locus on the short arm of chromosome 3, compared with only 13% at
the p53 tumour-suppressor gene and 6% at 17q21. LOH at chromsome 5q21 and 22q was uncommon
(2-3%). Detailed analysis of the regions of LOH on chromsome 3p suggested that, in addition to the VHL
gene in chromosome 3p25-p26, mutations in one or more tumour-suppressor genes in chromosome 3pl3-p24
may be involved in the pathogenesis of sporadic renal cell carcinoma (RCC). We also confirmed previous
suggestions that chromosome 3p allele loss is not a feature of papillary RCC (P<0.05).
Renal cell carcinoma (RCC) is an important human cancer
whose aetiology is poorly understood. A small proportion of
cases (approximately 2%) occur in patients with an inherited
predisposition to RCC (Maher & Yates, 1991). The most
common hereditary form of RCC is von Hippel-Lindau
(VHL) disease, a dominantly inherited familial cancer synd-
rome predisposing to retinal and central nervous system
haemangioblastomas, RCC and phaeochromocytoma (Maher
et al., 1990a). Affected patients not only have a high pro-
bability of developing RCC (70% at age 60 years), but also
have an early age at onset and frequently develop multiple
tumours (Maher et al., 1990a, b). The gene for VHL disease
has been mapped to chromosome 3p25-p26 (Seizinger et al.,
1988; Hosoe et al., 1990; Maher et al., 1991; Seizinger et al.,
1991a; Crossey et al., 1993a; Richards et al., 1993) and
appears to function as a tumour-suppressor gene (Tory et al.,
1989; Maher et al., 1990b; Crossey et al., 1993b; Latif et al.,
1993). Another familial RCC gene (RCCI) also maps to the
short arm of chromosome 3: Cohen et al. (1979) reported a
large family in which a balanced translocation between
chromosome 3 and 8 was associated with a predisposition to
early-onset multicentric RCC. The translocation breakpoint
was at chromosome 3pl4, suggesting that mutations in two
genes on chromsome 3p (VHL at 3p25-p26 and RCCI at
3pl4) may cause familial RCC.
Mutations in one or more tumour-suppressor genes on
chromosome 3p have also been implicated in the patho-
genesis of non-familial RCC (Maher & Yates, 1991).
Shimuzu et al. (1990) found that the effect of introducing a
normal chromosome 3p into a RCC cell line was to suppress
its tumorigenicity. In addition, cytogenetic and molecular
studies of sporadic RCC have shown frequent chromosome
3p deletions (Zbar et al., 1987; Kovacs et al., 1988;
Bergerheim et al., 1989; Anglard et al., 1991; Van der Hout
et al., 1991; Yamakawa et al., 1991). The VHL and RCCI
genes are candidate genes for non-familial RCC, but
molecular genetic studies of chromosome 3p allele loss in
sporadic RCC have yielded conflicting results about the
localisation of the critical region of allele loss: Van der Hout
et al. (1991) suggested 3p2l, Yamakawa et al. (1991) sug-
gested 3pl4 and 3p2l, and Bergerheim et al. (1989) and
Anglard et al. (1991) suggested chromosome 3p2l-p26,
which would include the VHL disease locus. In addition to
allele loss on chromosome 3p, loss of heterozygosity has been
reported on several other chromosomes (including 5, 11 and
17) in sporadic RCC (Anglard et al., 1991; Morita et al.,
1991). We have analysed non-familial RCC for allele loss in
the region of known or putative tumour-suppressor genes on
the short arm of chromosome 3 and on chromosomes 5, 11,
17 and 22 to investigate the molecular pathogenesis of
sporadic RCC.
Materials and methods
Patient and tumour material
Paired blood-tumour samples (n = 55) from 55 patients (41
male, 14 female, mean age 56 years, range 22-77 years) with
non-familial RCC were analysed for loss of heterozygosity at
14 loci located close to known or putative tumour-suppressor
genes. All tumours samples were taken from primary
tumours in previously untreated patients, and were snap
frozen in liquid nitrogen and stored at - 30'C or - 70'C
until analysed. All patients had a histologically proven diag-
nosis of RCC.
Molecular genetic analysis and detection ofallete loss
High molecular weight DNA was isolated from peripheral
blood and frozen tumour tissue by standard methods (Sam-
brook et al., 1989). Details of the loci investigated are given
in Table I: eight loci mapped to chromosome 3p and six to
other chromosomes. The locations of the chromosome 3p
probes are given in Table I and in Figure 1. Three areas on
chromsome 3p were of particular interest (see above): (i)
chromosome 3pl4 (D3S659 and D3S1067 flank the transloca-
tion breakpoint; Yamakawa et al., 1992), (ii) chromosome
3p2l -p24, a region that shows frequent LOH in a variety of
tumour types, and (iii) chromosome 3p25-p26 close to the
VHL disease tumour-suppressor gene (the locus order within
this region is D3S651-D3S1038-D3S1317-VHL). The other
loci were selected because they map close to tumour-
suppressor genes: (i) APC/MCC genes at chromosome 5q21,
(ii) WT2 gene in chromosome 1 lp15.5, (iii) chromosome 17p
(the p53 tumour-suppressor gene maps to 17p13.1 and we
also investigated a marker at 17pl3.2), (iv) chromsome 17q
[the familial breast cancer gene (BRCAI) is located at
17q21], (v) the neurofibromatosis type 2 (NF2) gene on
chromosome 22.
For the analysis of microsatellite markers (see Table I)
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Table I Details of loci investigated for loss of heterozygosity
Jones et al. (1992)
Jones et al. (1992)
Jones et al. (1992)
Jones et al. (1992)
Jones et al. (1992)
Jones et al. (1992)
Jones et al. (1992)
Tory et al. (1993)
Spirio et al. (1993)
Saito et al. (1992), Jones et al. (1993)
Jones et al. (1993)
Jones and Nakamura (1992)
S. Smith and B.A.J. Ponder
(personal communication, 1993)
Marineau et al. (1993)
pter
26
25
24.1
24.2
7)
I
D3S1317
D3S1038
D3S651
,1..
23 D3S647
22
21.3
21.2
21.1 D3S1067
14.3 D3S1076
14.2
14.1 D3S1228
13 D3S659
12
CEN
Figure I Localisation of chromosome 3p loci investigated.
DNA was amplified by the polymerase chain reaction (PCR)
as described previously (Crossey et al., 1993a, b). DNA
(50 ng) was amplified by PCR in 20 ftl reactions containing
standard PCR buffer (10 mM Tris-Cl pH 8.8, 50 mM potas-
sium chloride, 0.01% gelatin, 1.5 mM magnesium chloride,
10pmol of each primer, 0.1 pmol of end-labelled primer,
200 tLM each of dATP, dCTP, dGTP and dTTP, and 0.5 U of
Taq polymerase. The samples were subjected to 20-30 PCR
amplification cycles of 1 min denaturation at 94°C, 1 min
annealing at 50-60°C and 1 min extension at 72°C. The PCR
products were mixed with an equal volume of formamide
loading buffer, heat denatured and then fractionated on a
6% polyacrylamide-6 M urea gel using a sequencing reaction
as a size marker. Gels were dried and exposed for 1-3 days
at -20°C.
Results
Chromosome 3p
All 55 tumours were informative at one or more loci on
chromosome 3p, and overall 35 (64%) tumours showed LOH
at one or more loci on chromosome 3p (see Table II). The 35
tumours with LOH on chromosome 3p could be divided into
four groups according to the pattern of LOH: group a, 15
tumours showed LOH at all informative loci on chromosome
3p (tumours 6, 10, 11, 16, 17, 20, 23, 27, 29, 35, 36, 38, 42,
48, 54); group b, 15 tumours had LOH on chromosome
3pl3-p24, but retention of heterozygosity in chromosome
3p25-p26 (tumours 4, 7, 12, 14, 15, 18, 19, 21, 22, 34, 37, 41,
44, 46, 53); group c, four tumours showed partial chromo-
some 3p allele loss including chromosome 3p25-p26 (1, 33,
40, 50); group d, tumour 9 showed a more complicated
pattern with two non-contiguous regions of LOH. There
were no significant correlations between chromosome 3p
allele loss and sex or age at diagnosis. However, none of the
four tumours classified as papillary RCC on histopatho-
logical examination (tumours 24, 39, 49 and 52) showed
LOH on chromosome 3p, compared with 35 of 51 non-
papillary RCC [X2 (with Yates' correction) = 4.88, P<
0.05].
Other regions
The results of loss of heterozygosity studies on chromosomes
5, 11, 13, 17 and 22 are shown in Table III. 1/46 (2%)
informative tumours showed LOH at chromosome 5q21, 1/
35 (3%) at chromosome 17pl3.2, 5/39 (13%) at p53, 2/35
(6%) at chromosome 17q21 and 1/40 (3%) at D22S268 (see
Figure 2). There was no relationship between the presence or
absence of LOH at chromosome 3p and at other locations (4
of 35 tumours with chromosome 3p LOH had LOH and 3 of
20 with no chromosome 3p LOH had LOH at a non-
chromosome 3 locus respectively; x2 = 0.15, P>0.1).
Discussion
We have confirmed that chromosome 3p allele loss is the
most frequent abnormality in sporadic RCC. Three candidate
regions have been proposed to contain RCC tumour-
suppressor genes (3p25-p26, 3p2l and 3pl3-pl4). The
recent cloning of the VHL disease gene and the demonstra-
tion of inactivating mutations in five sporadic RCC cell lines
has confirmed the hypothesis that VHL gene mutations are
involved in the pathogenesis of sporadic RCC (Latif et al.,
1993). Each of the five RCC cell lines reported by Latif et al.
(1993) contained a large chromosome 3p deletion (so that
one VHL allele was lost) and a VHL gene mutation on the
cytogenetically normal chromosome 3. Further studies to
define the proportion of primary sporadic RCC with VHL
gene mutations are in progress. Nevertheless, analysis of the
pattern of allele loss in group B tumours suggests that other
loci on the short arm of chromosome 3, in addition to the
VHL gene, may be involved in the pathogenesis of sporadic
RCC. Fifteen tumours showed chromosome 3p allele loss
that did not involve the VHL region. Detailed analysis of the
pattern of LOH in these tumours suggested two conclusions.
Heterozygosity Reference Locus
D3S659
D3S1228
D3S1076
D3S1067
D3S647
D3S651
D3S1038
D3S1317
D5S346
D111S576
CI 17-732CA
p53
D17S588
D22S268
Location
3p13
3pl4.1 - 14.3
3p21.1
3p14.3-p21.1
3p23
3p25
3p25
3p25-p26
5q21
lIplS.5
17p13.2
17pl3.1
17q21
22q12
0.73
0.77
0.59
0.86
0.73
0.34
0.80
0.70
0.5
0.55
0.60
0.90
0.45
0.71232 K. FOSTER et al.
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Figure 2 Examples of loss of heterozygosity at loci on chromosome 3p (tumour 36) and 17 (tumours 36 and 32 respectively). Key:
B = blood DNA; T = tumour DNA.
Firstly, if a single tumour-suppressor gene was involved it
should be located centromeric to D3S1067 (see tumours 4,
21, 37, 44 and 46) and telomeric to D3S1076 (see tumour 34).
However this conclusion is dependent on the deletion in
tumour 34 overlapping with that in tumour 4, 21, 37, 44 or
46, and this could not be determined because DNA markers
mapping between D3S1067 and D3S1076 were not available
for study. The alternative conclusion would be that if the
deletion in tumour 34 and those in tumours 4, 21, 37, 44 or
46 did not overlap then two tumour-suppressor genes, at
3pl4 and 3p2l, might be involved, as suggested by
Yamakawa et al. (1991). Following the isolation of the RCCI
gene it will be possible to investigate the role of RCCI
mutations in the pathogenesis of sporadic RCC. In addition,
the isolation and accurate mapping of more microsatellite
markers from chromosome 3pl4-p21 would enable the
critical region of chromosome 3p allele loss in sporadic RCC
to be defined more precisely.
Human carcinogenesis is characteristically a multistep pro-
cess in which mutations accumulate in a restricted number of
tumour-suppressor genes and oncogenes. Although chromo-
some 3p allele loss is a frequent event in sporadic RCC,
mutations in other tumour-suppressor genes may also occur.
Morita et al. (1991) reported chromosome 17p and Sq allele
loss in 5/24 and 5/17 RCCs respectively. However, Horii et
al. (1992) did not detect any APC gene mutations in RCC
with chromosome 5q LOH and suggested that another
tumour-suppressor gene on chromosome 5q might contribute
to the pathogenesis of RCC. The lower rates of LOH at
chromosome 5q21 and 22q found by us (1/46 and 1/40
informative tumours respectively) are similar to those
reported by van der Hout et al. (1991) (0/9 and 0/8 respec-
tively). We detected LOH on chromosome 17 most fre-
quently in the region of the p53 tumour-suppressor gene,
although most tumours with LOH at p53 also demonstrated
LOH at other chromosome 17 loci investigated. Although
p53 mutations are the most frequent genetic abnormality in
human cancer, the frequency of p53 involvement in sporadic
RCC is less than in many other tumour types. We found
LOH at the p53 locus in only 13% of informative tumours,
which is similar to the findings of van der Hout et al. (1991)
(12.5% LOH on 17p), Anglard et al. (1991) (11% LOH on
chromosome 17), Torigoe et al. (1992) (10% p53 mutations),
Whaley et al. (1990) (7% p53 mutations) and Suzuki et al.
(1992) (4.3% p53 mutations). It has been suggested that
chromosome 3p allele loss is an early event in RCC, but that
other tumour-suppressor gene mutations are involved in
tumour progression. Anglard et al. (1991) found that LOH at
chromosome lip and 13 was not present in localised
tumours but was frequent in stage IV tumours. Kovacs et al.
(1989) related the histopathological features of non-familial
RCC with the molecular pathology, and suggested that
chromosome 3p allele loss is infrequent in the papillary
subgroup of RCC. Our findings also support this associa-
tion.
The isolation of hereditary cancer genes will allow their
role in the pathogenesis of non-familial RCC to be investi-
gated by direct mutation analysis. Such studies should also
elucidate the relationship between RCC tumour-suppressor
genes and the molecular pathology of other human cancers,
such as lung, breast, ovary, uterus and testis cancer, which
show frequent chromosome 3p allele loss (Seizinger et al.,
1991b).
We thank the Cancer Research Campaign, Action Research and the
National Kidney Research Fund for financial support and the many
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